Novartis Reports P-III (RemIND) Trial Data on Remibrutinib for Chronic Inducible Urticaria (CIndU)

Why It Matters

The trial demonstrates remibrutinib’s potential as the first targeted therapy to address antihistamine‑refractory CIndU, opening a sizable market and expanding Novartis’s dermatology portfolio.

Key Takeaways

• Remibrutinib achieved 29.3% complete response in symptomatic dermographism.
• Cold urticaria patients showed 56.3% complete response at week 12.
• Responses emerged as early as week 2 in two CIndU subtypes.
• Novartis submitted sNDA for Rhapsido, aiming worldwide approval in 2026.

Pulse Analysis

Chronic inducible urticaria (CIndU) encompasses a group of mast‑cell driven skin disorders—such as symptomatic dermographism, cold urticaria, and cholinergic urticaria—where patients experience recurrent wheals triggered by physical stimuli. Standard care relies on H1‑antihistamines, yet a substantial subset remains inadequately controlled, leading to impaired quality of life and frequent healthcare visits. The unmet therapeutic gap has spurred interest in targeted approaches that interrupt key signaling pathways, notably Bruton’s tyrosine kinase (BTK), which mediates mast‑cell activation and degranulation.

In the Phase III RemIND trial, Novartis evaluated oral remibrutinib (branded Rhapsido) against placebo in a rigorously selected adult CIndU cohort. The study reported striking complete response rates at week 12: 29.3% for symptomatic dermographism, 56.3% for cold urticaria, and 29.3% for cholinergic urticaria. Notably, therapeutic effects surfaced as early as week two in two of the three subtypes, suggesting rapid symptom control. These outcomes surpass historical response benchmarks for antihistamine‑only regimens and position remibrutinib as a disease‑modifying option rather than a symptomatic band‑aid.

Building on the clinical promise, Novartis has filed a supplemental New Drug Application (sNDA) with the FDA to secure approval for symptomatic dermographism, with plans to extend regulatory submissions worldwide throughout 2026. If cleared, Rhapsido would become the first BTK‑inhibitor indicated for CIndU, potentially capturing a multi‑billion‑dollar market segment and reinforcing Novartis’s leadership in dermatology innovation. The forthcoming regulatory decisions will also influence competitor pipelines, prompting other biotech firms to accelerate their own targeted mast‑cell therapies. Overall, the RemIND data signal a paradigm shift toward precision treatment for patients who have exhausted conventional antihistamine therapy.